Berberine and Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease Clinical Trial

— NAFLD  

Official title:

The Effect of Berberine on Lipid Profile, Liver Enzymes and Fasting Blood Glucose in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04049396
• Other study ID #: IR.IAU.SRB.REC
• Status: Completed
• Phase: N/A
• Start date: October 1, 2018
• Est. completion date: June 15, 2019

Study information

• Verified date: August 2019
• Source: Islamic Azad University, Tehran
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Non-alcoholic fatty liver disease (NAFLD), one of the most common liver dysfunctions, affects about one-fourth of the global adult population and has a significant mortality rate between 6.3% and 33%.NAFLD can lead to other serious illnesses. The disease is associated with a group of metabolic comorbid conditions, including type 2 diabetes mellitus (T2DM), obesity, hypertension, and hyper-cholesterolemia, which are potential risk factors for progressive liver disease.This study sought to evaluate the therapeutic effect of berberine on the liver function and metabolic profiles of patients with NAFLD. In this context,A six week, open-label randomized controlled trial was conducted in a single medical center at Takestan Hospital, Iran. A total of 281 patients with NAFLD were enrolled and randomly assigned to treatment arm with (n=24) or without (n=24) berberine. All patients had received pre-randomization lifestyle training including recommendations on low-fat diet. Blood examinations were performed to evaluate glucose, lipid profile, and liver enzymes both at the beginning of the study and upon the completion of the trial (day 45). To assess tolerability of the study intervention and any possible adverse events, patients in both groups were required to attend weekly follow-up visits.

Description:

A seven-week (45-day), open-label, randomized controlled trial was conducted in a medical center affiliated with the Ministry of Welfare and Social Security in Iran to study the impact of berberine on liver function and metabolic profiles of patients with NAFLD. Hospital employees who met the enrollment criteria were identified through electronic health records (EHRs) available in a human resource database of employee routine annual examinations. Using a computer-generated random-allocation sequence, eligible employees were equally assigned (1:1) to berberine 6.25 g per day (arm A) or no intervention (Arm B). Berberine was administered orally (100 g dried berberine in 5 Liter water boiled at 167°F until 4Liter).). To control the potential impact of confounders on outcome measures, and to balance the daily dietary and physical activity among the study groups, all participants were trained by skilled experts on lifestyle and behavior improvement.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: June 15, 2019
• Est. primary completion date: March 25, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients must have an age range between 18 to 65 years(inclusive).

• Patients with Liver fat content assessed by MRS=13%.

• Patients must meet the criteria for impaired glucose regulation

• Course of diabetic mellitus less than 1 year

• Informed consent signed

Exclusion Criteria:

• Any causes of chronic liver disease other than NAFLD(such as-but not restricted to- alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, etc.);

• Patients with significantly impaired liver function: ALT or AST=2 times upper limit of normal;

• Patients with type 1 diabetes mellitus or gestational diabetes or special type diabetes;

• Course of diabetes more than 1 years;

• Diabetics patients who have taken or are taking oral glucose-lowering drugs or insulin;

• Diabetics patients with a HbA1c>7.5% on initial visit;

• Patients with severe diabetes complications(diabetes ketoacidosis, diabetes coma or with symptomatic of diabetes coma; dysfunction of nerve, retinopathy, dysfunction of kidney);

• Patients with a history of clinically significant heart disease(myocardial infarct, heart failure, and/or severe cardiac rhythm);

• Complicating severe infection,within 6 months after operation, severe trauma;

• Patients with excess alcohol consumption=140g/week(male); =70g/week(female);

• Patients have participated other clinical trials within 24 weeks;

• Patients with a history of drug allergy to berberine;

• Patients with gestation or possible gestation or lactation, or males or females expecting gestation during clinical trial;

• Mental diseases patients;

• Those who refuse to sign informed consent;

• Any other conditions, which, in the opinion of the investigators would impede competence or compliance or possibility of hindering completion of the study;

• Patients with serum triglyceride=5.0mmol/L;

• Patients with thyroid disease, including hyperthyroidism or hypothyroidism.

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease

Intervention

Other:
• Berberine
24 Patient consumed 6,25 g/day Berberine for 6 weeks

Locations

Country	Name	City	State
Iran, Islamic Republic of	Sciences & Research Branch,Azad University of Tehran	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
Lida Nejati

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline of Alanine Aminotransferase (ALT)	Serum Alanine Aminotransferase concentration (units per liter)	Baseline and 6 weeks after
Primary	Change from baseline of Aspartate Aminotransferase (AST)	Serum Aspartate Aminotransferase concentration(units per liter)	Baseline and 6 weeks after
Primary	Change from baseline of Alkaline Phosphatase( ALP)	Serum Alkaline Phosphatase concentration (units per liter)	Baseline and 6 weeks after
Secondary	Change from baseline of fasting blood sugar(FBS)	Fasting blood sugar concentration (mg/dl)	Baseline and 6 weeks after
Secondary	Change from baseline of total cholesterol (TC)	Serum total cholesterol concentration (mg/dl)	Baseline and 6 weeks after
Secondary	Change from baseline of LDL-Cholesterol	Serum LDL-Cholesterol concentration (mg/dl)	Baseline and 6 weeks after
Secondary	Change from baseline of HDL - Cholesterol	Serum HDL-Cholesterol concentration (mg/dl)	Baseline and 6 weeks after
Secondary	Change from baseline of Triglyceride (TG)	Serum Triglyceride concentration (mg/dl)	Baseline and 6 weeks after